Cefi- L : Scientific References/Vaf/Strategy

The correct answer is Beta Lactam with Quinolone can be given as empirical First line therapy in LRTI. This is supported by the endorsement of BMC Infectious Disease 2011.

The correct answer is 1 tablet once daily for a period of 7 days. This means that the recommended dosage of Cefi-L is to take one tablet every day for a total of 7 days. This dosage regimen ensures that the medication is taken consistently and for a sufficient duration to effectively treat the condition for which it is prescribed.

The combination of Cefixime 400 + Levofloxacin 500 is rational because Cefixime has excellent Gram negative activity, while Levofloxacin is very active against Gram positive and atypical bacteria. This combination allows for broad coverage against both types of bacteria, making it an effective treatment option.

The ZSM input for the month of July for Cefi-L is a Table Fan.

Cefi-L is not recommended in pregnancy.

Levofloxacin shows a high level of susceptibility against S.pneumoniae, with a rate of 99%. This means that 99% of S.pneumoniae strains are susceptible to the antibiotic Levofloxacin, indicating that it is an effective treatment option for infections caused by this bacterium.

The European Respiratory Society 2011 guidelines recommend a combination of Levofloxacin and Cephalosporin in the treatment of Lower Respiratory Tract Infections (LRTI). This combination is likely to be effective in combating the infection and reducing symptoms. It is important to follow these guidelines to ensure appropriate treatment and improve patient outcomes.

The number of P1/P2 drs for Cefi-L is 15.

The punch line "Superior coverage Improves Clinical Outcome" suggests that having better coverage leads to improved clinical outcomes. This implies that when patients have superior coverage, they are more likely to receive the necessary medical treatments and interventions, resulting in better health outcomes. This could include access to a wider range of treatments, medications, and healthcare services. Ultimately, the punch line highlights the importance of having comprehensive coverage for better patient outcomes.

All of the brands mentioned, Taxim-O, Cefolac, and Ceftas, are competitors for Cefi-L. This means that all these brands are in the same market and offer similar products or services as Cefi-L. Therefore, they compete with each other for customers and market share.

The correct answer is "Journal of Antimicrobial Chemotherapy." This journal specifically focuses on the benefits of combination therapy in the field of antimicrobial treatment. It likely contains research articles, case studies, and reviews that discuss the advantages of using multiple antimicrobial drugs together, such as increased effectiveness, reduced development of resistance, and improved patient outcomes.

The correct answer is 1 CME/ASM/CYCLE. This means that one Continuing Medical Education (CME) is expected from one Advanced Selling Method (ASM) in one sales cycle. This suggests that the ASM is responsible for providing one CME during the entire sales cycle.

The Merck Manual & Martindale is a standard medical textbook that clearly mentions the dosage of cefixime. It is a reliable source of information for healthcare professionals regarding the appropriate dosage of drugs.

The correct answer is "Macrolide resistant S.Pneumoniae." JAC (Joint Advisory Committee on Antibiotic Use) recommends the combination of Levofloxacin and Cephalosporin for the treatment of Macrolide resistant S.Pneumoniae. This suggests that Levofloxacin and Cephalosporin are effective against this specific type of bacteria when it is resistant to Macrolide antibiotics.

The objective of "LRTI News Letter" is to create awareness about LRTI infections and its treatment, as well as to highlight the advantage of the combination in LRTI management. This means that the newsletter aims to provide information about LRTI infections, their treatment options, and the benefits of using a combination approach in managing LRTI.